Wanbury Limited has informed the Exchange regarding a press release dated April 28, 2026, titled "Press release on MFDS (Ministry of Food and Drug Safety - Korea FDA) Regulatory Inspection".
WANBURY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Wanbury Limited's Patalganga manufacturing site successfully completed a regulatory inspection by MFDS (Korea FDA) from April 7-9, 2026. The three-day inspection resulted in zero observations, confirming cGMP compliance per international standards. MFDS is part of PIC (Pharmaceutical Inspection Co-operation Scheme). The company also highlighted that both its API manufacturing sites (Patalganga and Tanuku) hold USFDA approval, and Tanuku previously received zero observation from Brazil's ANVISA. Wanbury is expanding infrastructure with a new manufacturing block at Andhra Pradesh for new APIs under validation.
A zero observation from Korea FDA is a strong positive signal, reinforcing Wanbury's quality compliance credentials across multiple international regulatory bodies including USFDA, ANVISA, and now MFDS. This strengthens the company's credibility for export orders and global pharmaceutical contracts.